Viz.ai, an artificial intelligence (AI)-powered disease detection and care coordination company, has launched a new software to accelerate diagnosis and care for lung disease patients.
The latest software features natural language processing (NLP) and imaging AI.
The enhancement allows Viz.ai to extract clinical insights from electronic health records (EHR) to identify and manage lung disease patients.
The updated software will be integrated into Viz.ai’s platform, speeding up the care process and improving patient outcomes.
Viz.ai new markets & growth head Jack Manley said: “The signs and symptoms of lung disease are often subtle and easily confused with the symptoms of other common diseases, making it difficult to discern the appropriate route of care.
“With more than 35 million people in the US living with a lung disease like asthma or COPD1, and with lung cancer remaining the leading cause of cancer deaths2, Viz’s AI-powered platform has the potential to accelerate the time it takes patients to receive an accurate diagnosis, getting to the right specialist and treatment at the right time, thereby preventing life-threatening events and hospitalisations.”
Viz.ai is expanding its pulmonary solutions along with the expansion of the Viz Pulmonary Embolism (PE) feature with right ventricular strain.
This update will use NLP to analyse EHR data and imaging AI to identify and triage patients suspected of lung disease for further follow-up and care.
The new features will be integrated into Viz.ai’s AI-powered care acceleration platform. This will help healthcare providers streamline care pathways, manage high-risk patient referrals, and improve overall patient outcomes.
The disease detection and care coordination company is collaborating with research centres and patient-advocacy groups to fight lung disease.
Recently, it partnered with the Addario Lung Cancer Medical Institute (ALCMI), an international group of 25 lung cancer research institutions. This partnership aims to enhance early detection and optimise clinical workflows for lung cancer patients.
Viz.ai aims to use AI algorithms and machine learning to enhance diagnosis and care in the US and Europe.
Its AI-powered solution, Viz.ai One, is designed for intelligent care coordination. It identifies more patients with suspected diseases, informs critical decisions at the point of care, and optimises care pathways, leading to improved outcomes.
In June this year, Viz.ai partnered with the Hypertrophic Cardiomyopathy Association (HCMA) to support, educate and advance research to improve care for patients with hypertrophic cardiomyopathy (HCM).
